Valeo Financial Advisors LLC Sells 1,157 Shares of Laboratory Co. of America Holdings (NYSE:LH)

Valeo Financial Advisors LLC lessened its holdings in shares of Laboratory Co. of America Holdings (NYSE:LH) by 16.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 6,012 shares of the medical research company’s stock after selling 1,157 shares during the period. Valeo Financial Advisors LLC’s holdings in Laboratory Co. of America were worth $1,344,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Insight Inv LLC grew its holdings in shares of Laboratory Co. of America by 1.3% during the second quarter. Insight Inv LLC now owns 3,530 shares of the medical research company’s stock worth $718,000 after purchasing an additional 45 shares during the last quarter. Athena Investment Management boosted its holdings in Laboratory Co. of America by 4.8% in the second quarter. Athena Investment Management now owns 1,040 shares of the medical research company’s stock valued at $212,000 after acquiring an additional 48 shares during the last quarter. Unison Advisors LLC boosted its holdings in Laboratory Co. of America by 0.5% in the first quarter. Unison Advisors LLC now owns 11,053 shares of the medical research company’s stock valued at $2,415,000 after acquiring an additional 51 shares during the last quarter. Connecticut Wealth Management LLC boosted its holdings in Laboratory Co. of America by 1.8% in the first quarter. Connecticut Wealth Management LLC now owns 2,973 shares of the medical research company’s stock valued at $649,000 after acquiring an additional 52 shares during the last quarter. Finally, Pure Financial Advisors LLC boosted its holdings in Laboratory Co. of America by 5.1% in the second quarter. Pure Financial Advisors LLC now owns 1,089 shares of the medical research company’s stock valued at $222,000 after acquiring an additional 53 shares during the last quarter. Institutional investors own 95.94% of the company’s stock.

Laboratory Co. of America Trading Up 0.7 %

NYSE LH opened at $216.39 on Friday. The firm has a market cap of $18.24 billion, a P/E ratio of 43.54, a P/E/G ratio of 1.67 and a beta of 1.05. The company has a debt-to-equity ratio of 0.39, a current ratio of 0.88 and a quick ratio of 0.77. The stock’s 50-day moving average is $223.63 and its 200-day moving average is $212.00. Laboratory Co. of America Holdings has a one year low of $191.97 and a one year high of $238.46.

Laboratory Co. of America (NYSE:LH) last released its quarterly earnings results on Thursday, August 1st. The medical research company reported $3.94 EPS for the quarter, topping analysts’ consensus estimates of $3.78 by $0.16. The company had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.19 billion. Laboratory Co. of America had a return on equity of 15.39% and a net margin of 3.60%. Laboratory Co. of America’s revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm posted $3.42 earnings per share. Sell-side analysts anticipate that Laboratory Co. of America Holdings will post 14.56 earnings per share for the current fiscal year.

Laboratory Co. of America Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 13th. Investors of record on Tuesday, November 26th will be given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.33%. The ex-dividend date of this dividend is Tuesday, November 26th. Laboratory Co. of America’s dividend payout ratio is presently 57.95%.

Analyst Ratings Changes

LH has been the topic of several recent research reports. Bank of America raised their price target on Laboratory Co. of America from $240.00 to $260.00 and gave the company a “buy” rating in a report on Monday, August 5th. UBS Group raised their price target on Laboratory Co. of America from $260.00 to $270.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Jefferies Financial Group raised their price target on Laboratory Co. of America from $245.00 to $265.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Robert W. Baird raised their price target on Laboratory Co. of America from $278.00 to $282.00 and gave the company an “outperform” rating in a report on Friday, September 20th. Finally, Evercore ISI reduced their target price on Laboratory Co. of America from $250.00 to $240.00 and set an “in-line” rating on the stock in a report on Tuesday, September 24th. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, Laboratory Co. of America presently has an average rating of “Moderate Buy” and a consensus price target of $253.00.

Insider Activity at Laboratory Co. of America

In related news, EVP Lance Berberian sold 12,093 shares of Laboratory Co. of America stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $229.10, for a total value of $2,770,506.30. Following the sale, the executive vice president now owns 15,921 shares of the company’s stock, valued at approximately $3,647,501.10. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $227.05, for a total value of $454,100.00. Following the completion of the transaction, the executive vice president now directly owns 3,670 shares in the company, valued at $833,273.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Lance Berberian sold 12,093 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $229.10, for a total value of $2,770,506.30. Following the completion of the transaction, the executive vice president now owns 15,921 shares of the company’s stock, valued at approximately $3,647,501.10. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 29,679 shares of company stock valued at $6,716,306. 0.85% of the stock is owned by insiders.

Laboratory Co. of America Profile

Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.